FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.
2 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Goldman Sachs
American investment bank
Related events
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.
- Kevin Sabet advises on the FDA's drug policy process, which is being reported on in public hearings.
Coverage
Newest first; wire copies grouped- StockStoryThe 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market respond
- Motley Fool7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promisin